{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mai Q"],"funding":["Guangdong Key Laboratory of Immune Regulation and Immunotherapy","Basic and Applied Basic Research Foundation of Guangdong Province","National Natural Science Foundation of China","Guangdong Natural Science Foundation Outstanding Youth Project"],"pagination":["85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11334566"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Epstein-Barr virus (EBV) related post-transplant lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), for which no standard therapeutic means have been developed. Significant increase expression of natural killer group 2 member D ligands (NKG2DLs) was observed on B-lymphoblastoid cells of EBV-PTLD, indicating NKG2DLs as potential therapeutic targets for treatment of EBV-PTLD. In this study, the recombinant constructs of NKG2D CAR and IL-15/IL-15Rα-NKG2D CAR were generated with a retroviral vector and then transduced to human T cells to produce NKG2D CAR-T and IL-15/IL-15Rα-NKG2D CAR-T cells, respectively. B-lymphoblastoid cell lines (B-LCLs) and the xenografted mouse models were"],"journal":["Experimental hematology & oncology"],"pubmed_title":["Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder."],"pmcid":["PMC11334566"],"funding_grant_id":["2022B1515020050","2022A1515110828","82300252","2023A1515110236","2022B1212010009"],"pubmed_authors":["Deng S","Zeng Q","Li J","Li C","Wang C","Fu Y","Huang L","Zhang L","Mai Q","Zhang S","Pang Y","Li T","Zeng J","Xu X","He B","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder.","description":"Epstein-Barr virus (EBV) related post-transplant lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), for which no standard therapeutic means have been developed. Significant increase expression of natural killer group 2 member D ligands (NKG2DLs) was observed on B-lymphoblastoid cells of EBV-PTLD, indicating NKG2DLs as potential therapeutic targets for treatment of EBV-PTLD. In this study, the recombinant constructs of NKG2D CAR and IL-15/IL-15Rα-NKG2D CAR were generated with a retroviral vector and then transduced to human T cells to produce NKG2D CAR-T and IL-15/IL-15Rα-NKG2D CAR-T cells, respectively. B-lymphoblastoid cell lines (B-LCLs) and the xenografted mouse models were","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-07-15T08:03:57.288Z","creation":"2025-04-05T21:20:43.079Z"},"accession":"S-EPMC11334566","cross_references":{"pubmed":["39160631"],"doi":["10.1186/s40164-024-00553-z"]}}